StockData
Senti Biosciences Holdings, Inc. logo

Senti Biosciences Holdings, Inc. (SNTI) shareholders

SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.10−0.04 (-28.68%)

Close on Nov 17, 2026Market cap $3.02MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
18.6%
6M of 31M shares
Institutional holders
19
6 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Celadon Partners SPV 24
Joint filing with Celadon Partners, LLC (54.60%), CPIF II-7 Limited (54.60%)
25,748,89054.60%13D (active) amendmentApr 27, 2026
CPIF II-7 Limited
Joint filing with Celadon Partners SPV 24 (54.60%), Celadon Partners, LLC (54.60%)
25,748,89054.60%13D (active) amendmentSep 3, 2026
Celadon Partners, LLC
Joint filing with Celadon Partners SPV 24 (45.00%)
13,511,32245.00%13D (active) amendmentJan 19, 2026
Gurumurthy Ramamurthy
Joint filing with Bayer HealthCare LLC (19.99%), Bayer US Holding LLC (19.99%) and 1 more
6,142,84819.99%13D (active)Mar 10, 2025
Bayer US Holding LLC
Joint filing with Bayer HealthCare LLC (17.82%), Sebastian Guth (17.82%) and 1 more
6,142,84817.82%13D (active) amendmentMar 27, 2026
Mohamad H. Makhzoumi
Joint filing with New Enterprise Associates 15, L.P. (12.10%), NEA Partners 15, L.P. (12.10%) and 4 more
3,775,61512.10%13D (active) amendmentMar 27, 2026
NEA Partners 15, L.P.
Joint filing with New Enterprise Associates 15, L.P. (14.50%), Nea 15 Gp, LLC (14.50%) and 4 more
3,775,61514.50%13D (active) amendmentMar 6, 2025
Daniel Mack
Joint filing with Nantahala Capital Management, LLC (8.12%), Wilmot B. Harkey (8.12%)
2,220,0008.12%13G (passive) amendmentMar 31, 2025
Armistice Capital, LLC
Joint filing with Steven Boyd (9.99%)
536,0109.99%13G (passive)Dec 31, 2024
Wilmot B. Harkey
Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%)
509,2839.99%13G (passive)Dec 31, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SNTIValueChange% of portfolio
NEA Management Company, LLC3,775,61512.12%$4.15M–0.26%
Nantahala Capital Management, LLC888,0002.85%$976.80K–0.02%
Vanguard Capital Management LLC537,5041.73%$591.25K–0.00%
Geode Capital Management, LLC187,0650.60%$205.78K−19,9780.00%
Citadel Advisors LLC107,1000.34%$117.81KNew0.00%
Vanguard Fiduciary Trust Co91,1930.29%$100.31K–0.00%
Jane Street Group, LLC52,5300.17%$57.78KNew0.00%
Menlo Ventures Management, L.P.35,7370.11%$39.31K–0.01%
Northern Trust Corp32,1540.10%$35.37K+15,3760.00%
XTX Topco Ltd23,6100.08%$25.97K+6,3330.00%
Virtu Financial LLC22,7950.07%$25.00KNew0.00%
UBS Group AG14,4320.05%$15.88K+5,7950.00%
Tower Research Capital LLC (TRC)7,3440.02%$8.08KNew0.00%
Royal Bank of Canada4,0150.01%$4.00KNew0.00%
BlackRock, Inc.4,0040.01%$4.40K−21,0700.00%
Barclays PLC7680.00%$845New0.00%
SBI Securities Co., Ltd.3340.00%$367–0.00%
Morgan Stanley1690.00%$186+90.00%
Caitong International Asset Management Co., Ltd10.00%$1–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026196M18.6%6 / 42 / 30M0M
Q1 2026166M18.1%7 / 31 / 41M0M
Q4 2025156M18.0%4 / 42 / 50M0M
Q3 2025166M18.8%5 / 42 / 40M1M
Q2 2025157M21.6%1 / 53 / 21M0M
Q1 2025166M19.0%4 / 70 / 45M0M
Q4 2024161M3.0%4 / 26 / 20M0M
Q3 2024141M3.4%5 / 62 / 100M0M
Q2 2024201M3.3%3 / 34 / 100M0M
Q1 2024271M3.5%7 / 33 / 50M0M
Q4 2023251M3.7%5 / 51 / 60M0M
Q3 2023261M3.9%3 / 55 / 50M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

9 funds held SNTI in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SNTIValue% of fundAs of
Vanguard Total Stock Market Index Fund368,8781.18%$405.77K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund168,6260.54%$185.49K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund95,8660.31%$91.23K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund24,7980.08%$23.60K0.00%May 31, 2026
Fidelity Total Market Index Fund19,9910.06%$19.02K0.00%May 31, 2026
Fidelity Series Total Market Index Fund18,8010.06%$17.89K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-100-0.00%-$110-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Timothy K. LuCEO, Director587,9491.89%Oct 23, 2026
Kanya RajangamPres. & Chief Med. & Dev. Off.87,8900.28%Oct 23, 2026
John Harry Cross IIIChief Financial Officer––Mar 11, 2025
Bryan Daniel BaumDirector––Jul 21, 2025
Donald F. TangDirector10,3680.03%Jun 27, 2025
Edward T. MathersDirector––Jun 27, 2025
James J. CollinsDirector176,1300.57%Jun 27, 2025
Fran SchulzDirector––Jun 27, 2025
Brenda CooperstoneDirector––Jun 27, 2025
Feng HsiungDirector––Jun 27, 2025
Partners SPV 24 Celadon10% owner9,777,00031.39%Mar 14, 2025
Mohamad Makhzoumi10% owner––Mar 12, 2025
Forest Baskett10% owner––Mar 12, 2025
World Investments B.V. Bayer10% owner––Mar 12, 2025
Anthony A. Florence Jr.10% owner3,775,61512.12%Mar 12, 2025
Scott D. Sandell10% owner442,6151.42%Mar 12, 2025
US Holding LP Bayer10% owner2,809,8489.02%Mar 12, 2025
Healthcare Llc Bayer10% owner––Mar 12, 2025
New Enterprise Associates 15, L.P.10% owner––Mar 12, 2025
Nea 15 Gp, Llc10% owner4,426,15114.21%Mar 12, 2025
NEA Partners 15, L.P.10% owner––Mar 12, 2025
Aktiengesellschaft Bayer10% owner––Mar 12, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Oct 21, 2026Tax withholding−19,953––54,890
Timothy K. Lu
CEO, Director
Oct 21, 2026Tax withholding−157,312––482,271
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Mar 9, 2026Tax withholding−10,757––74,843
Timothy K. Lu
CEO, Director
Mar 9, 2026Tax withholding−80,666––639,583
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Feb 2, 2026Tax withholding−1,384––85,600
Timothy K. Lu
CEO, Director
Feb 2, 2026Tax withholding−4,191––720,249
Partners SPV 24 Celadon
10% owner
Mar 10, 2025Conversion+9,777,000––9,777,000
US Holding LP Bayer
10% owner
Mar 10, 2025Conversion+2,222,000––2,809,848
Anthony A. Florence Jr.
10% owner
Mar 10, 2025Conversion+3,333,000––3,775,615
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Mar 10, 2025Conversion+33,000$2.25$74.25K33,000
Timothy K. Lu
CEO and Interim PFO and PAO, Director
Mar 7, 2025Award+642,358––724,440
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Mar 7, 2025Award+78,363––86,984
Timothy K. Lu
CEO, Director
Feb 6, 2025Sale−545$4.36$2.38K82,082
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Feb 6, 2025Sale−182$4.37$7958,621
Timothy K. Lu
CEO, Director
Feb 4, 2025Sale−3,922$4.07$15.96K82,627
Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
Feb 4, 2025Sale−1,297$4.07$5.28K8,803
Kanya Rajangam
Chief Medical & Devt. Officer
Feb 1, 2024Award+101,000––101,000
Deborah Knobelman
Chief Financial Officer
Feb 1, 2024Award+101,000––131,000
Timothy K. Lu
CEO and President, Director
Feb 1, 2024Award+306,000––865,496
Deborah Knobelman
Chief Financial Officer
Oct 3, 2022Award+30,000––30,000
Sponsor LLC Dynamics
Director, 10% owner
Jun 8, 2022Other−6,465,500––0
Sponsor LLC Dynamics
Director, 10% owner
Jun 8, 2022Option exercise+5,750,000––6,465,500
David R. Epstein
Director
Jun 8, 2022Award+112,519––123,252
Omid Farokhzad
Director
Jun 8, 2022Award+250,000$10.00$2.50M250,000
Omid Farokhzad
Director
Jun 8, 2022Other−4,518,097––1,947,403
Omid Farokhzad
Director
Jun 8, 2022Option exercise+5,750,000––6,465,500

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
3.58%
1M shares short
Days to cover
1.0
At 16M shares a day
Change since last report
+160.9%
From 0M shares
Short volume, 20 days
34.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Senti Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,629 shares on Aug 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Omid Farokhzad
Former Affiliate
Dec 2, 202483,277$179.88KDec 2, 2024Founder shares

See a number that looks wrong?